METFORMIN HYDROCHLORIDE tablet, film coated

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

Metformin Hydrochloride (UNII: 786Z46389E) (Metformin - UNII:9100L32L2N)

Pieejams no:

Proficient Rx LP

SNN (starptautisko nepatentēto nosaukumu):

Metformin Hydrochloride

Kompozīcija:

Metformin Hydrochloride 1000 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride tablets are contraindicated in patients with: Metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS .)

Produktu pārskats:

Metformin Hydrochloride Tablets are available as follows: 1000 mg: Bottles of 30 NDC 63187-332-30 Bottles of 60 NDC 63187-332-60 Bottles of 90 NDC 63187-332-90 Bottles of 100 NDC 63187-332-00 Metformin Hydrochloride Tablets, USP 1000 mg tablets are white to off-white, oval, biconvex, film coated tablets debossed on one side with S on the left side of bisect and G on the right side of bisect and other side 1 on the left side and 07 on the right side of the bisect. Store at 20°to 25° C (68°to 77° F); excursions permitted to 15° to 30° C (59° to 86° F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP. Manufactured by: Sciegen Pharmaceuticals Inc 20 Davids Drive Hauppauge NY 11788 Distributed by: Carlsbad Technology, Inc. 5923 Balfour Court Carlsbad, CA 92008 Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320 Rev: 01/14 Rx Only

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

METFORMIN HYDROCHLORIDE- METFORMIN HYDROCHLORIDE TABLET, FILM COATED
PROFICIENT RX LP
----------
METFORMIN HYDROCHLORIDE TABLETS USP
RX ONLY
LACTIC ACIDOSIS:
LACTIC ACIDOSIS IS A RARE, BUT SERIOUS, METABOLIC COMPLICATION THAT
CAN OCCUR DUE TO
METFORMIN ACCUMULATION DURING TREATMENT WITH METFORMIN HYDROCHLORIDE
TABLETS; WHEN IT
OCCURS, IT IS FATAL IN APPROXIMATELY 50% OF CASES. LACTIC ACIDOSIS MAY
ALSO OCCUR IN
ASSOCIATION WITH A NUMBER OF PATHOPHYSIOLOGIC CONDITIONS, INCLUDING
DIABETES MELLITUS, AND
WHENEVER THERE IS SIGNIFICANT TISSUE HYPOPERFUSION AND HYPOXEMIA.
LACTIC ACIDOSIS IS
CHARACTERIZED BY ELEVATED BLOOD LACTATE LEVELS (>5 MMOL/L), DECREASED
BLOOD PH, ELECTROLYTE
DISTURBANCES WITH AN INCREASED ANION GAP, AND AN INCREASED
LACTATE/PYRUVATE RATIO. WHEN
METFORMIN IS IMPLICATED AS THE CAUSE OF LACTIC ACIDOSIS, METFORMIN
PLASMA LEVELS >5 MCG/ML
ARE GENERALLY FOUND.
THE REPORTED INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS RECEIVING
METFORMIN HYDROCHLORIDE IS
VERY LOW (APPROXIMATELY 0.03 CASES/1000 PATIENT-YEARS, WITH
APPROXIMATELY 0.015 FATAL
CASES/1000 PATIENT-YEARS). IN MORE THAN 20,000 PATIENT-YEARS EXPOSURE
TO METFORMIN IN
CLINICAL TRIALS, THERE WERE NO REPORTS OF LACTIC ACIDOSIS. REPORTED
CASES HAVE OCCURRED
PRIMARILY IN DIABETIC PATIENTS WITH SIGNIFICANT RENAL INSUFFICIENCY,
INCLUDING BOTH INTRINSIC
RENAL DISEASE AND RENAL HYPOPERFUSION, OFTEN IN THE SETTING OF
MULTIPLE CONCOMITANT
MEDICAL/SURGICAL PROBLEMS AND MULTIPLE CONCOMITANT MEDICATIONS.
PATIENTS WITH CONGESTIVE
HEART FAILURE REQUIRING PHARMACOLOGIC MANAGEMENT, IN PARTICULAR THOSE
WITH UNSTABLE OR
ACUTE CONGESTIVE HEART FAILURE WHO ARE AT RISK OF HYPOPERFUSION AND
HYPOXEMIA, ARE AT
INCREASED RISK OF LACTIC ACIDOSIS. THE RISK OF LACTIC ACIDOSIS
INCREASES WITH THE DEGREE OF
RENAL DYSFUNCTION AND THE PATIENT'S AGE. THE RISK OF LACTIC ACIDOSIS
MAY, THEREFORE, BE
SIGNIFICANTLY DECREASED BY REGULAR MONITORING OF RENAL FUNCTION IN
PATIENTS TAKING METFORMIN
HYDROCHLORIDE TABLETS AND BY USE OF THE MINIMUM EFFECTIVE DOSE OF
METFORMIN HYDROCHLORIDE
TABLETS. IN